Pharmacy Clinical Policy Bulletins Aetna Medicare Prescription Drug Plan
Subject: Acne Agents, Oral
Status
Drug
PR-B/D
PR
PR-QL
PR-AL
ST
M EX‡
TOC§
C
Amnesteem™ (isotretinoin)
X
C
Claravis™ (isotretinoin)
X
C
doxycycline
X
C
isotretinoin
X
C
minocycline
X
C
Sotret™ (isotretinoin 10, 20 and 40mg)
X
NC
Accutane®(isotretinoin)
X
X
NC
Minocin Pac Kit®(minocycline cap w/acne care products)
X
X
NC
Sotret™ (isotretinoin 30mg)
X
X
NC
Solodyn®(minocycline SR tablet)
X
X
Note: Criteria for doxycycline and minocycline is discussed in the Pharmacy Clinical Policy Bulletin: Tetracyclines
Policy:
Precertification Criteria
Under some plans, including plans that use an open or closed formulary, Accutane, Amnesteem, Claravis, isotretinoin, Minocin Pac Kit, Solodyn and Sotret are subject to precertification. If precertification requirements apply Aetna considers Accutane, Amnesteem, Claravis, isotretinoin, Minocin Pac Kit, Solodyn and Sotret to be medically necessary for those members who meet of the following precertification criteria:
A. Diagnosis of severe recalcitrant nodular or cystic acne
AND
B. One of the following:
1. Member already has evidence of scarring OR
2. Contraindication to either systemic antibiotic, minocycline or doxycycline OR
3. Intolerance to either systemic antibiotic, minocycline or doxycycline OR
4. Failure of an adequate trial of one month of either systemic antibiotic, minocycline or doxycycline.
AND
C. If female, in accordance with FDA iPLEDGE program that requires completing an informed consent form, obtaining counseling about the risks and requirements for safe use of isotretinoin, and, for women of childbearing potential (non-hysterctomized), complying with required pregnancy testing and use of contraception, patient is not pregnant (report of negative pregnancy test obtained) and has been counseled about the use of reliable contraception 1 month before, during, and 1 month after isotretinoin therapy.
For Minocin Pac Kit and Solodyn
Under some plans, including plans that use an open or closed formulary, Minocin Pac Kit and Solodyn are subject to precertification for members less than or equal to 8 years of age. Aetna considers Minocin Pac Kit and Solodyn to be medically necessary for those members who meet the following precertification criteria:
A. Member's physician provides documentation (controlled clinical trial) from the peer-reviewed medical literature for medical use of Solodyn in patients younger than 12 years old for acne or in pediatric patients younger than or equal to 8 years old OR the medical use of Minocin Pac Kit in pediatric patients younger than or equal to 8 years of old.
Medical Exception Criteria
Accutane, Minocin Pac Kit, Solodyn and Sotret 30mg are currently Not Covered Part D drugs under the Aetna Medicare Prescription Drug Plan.* Therefore, they are excluded from coverage for members enrolled in prescription drug benefits plans that use a closed formulary, unless a medical exception is granted. Aetna considers Accutane, Minocin Pac Kit, Solodyn and Sotret 30mg to be medically necessary for those members who meet the following criteria:
For Accutane and Sotret 30mg
A. A documented:
Contraindication to one preferred generic alternative agent indicated for the member's condition OR
Intolerance to one preferred generic alternative agent indicated for the member's condition OR
Allergy to one preferred generic alternative agent indicated for the member's condition OR
Failure of an adequate trial of one month of one preferred generic alternative agent indicated for the member's condition
For Minocin Pac Kit and Solodyn
A. A documented:
Contraindication to one preferred generic minocycline product indicated for the member's condition OR
Intolerance to one preferred generic minocycline product indicated for the member's condition OR
Allergy to one preferred generic minocycline product indicated for the member's condition OR
Failure of an adequate trial of one month of one preferred generic minocycline product indicated for the member's condition
Special Notes:
Solodyn is an extended release, once-daily minocycline tablet that is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age or older. The safety of Solodyn has not been established beyond 12 weeks of use. Solodyn has not been evaluated in the treatment of infections. The use of drugs in the tetracycline class, the class Solodyn belongs too, may cause permanent teeth discoloration (yellow-gray-brown) during tooth development (last half of pregnancy, infancy and childhood up to the age of 8 years).
Place of Service:
Outpatient
The above policy is based on the following references:
Olin BR, editor. Drugs Facts and Comparisons (electronic online version). St. Louis: J.B. Lippincott Company, 2004.
USPDI Drug Information for the HealthCare Professional(online through Stat!Ref). Thomson MICROMEDEX,Greenwood Village,Colorado; 2004.
McEvoy GK, editor. AHFS Drug Information (online through Stat!Ref). American Society of Health-Systems Pharmacists,Bethesda,Maryland; 2004.
Medical Economics, Inc., PDR Electronic Library. Thomson Medical Economics,Montvale,NJ; 2003.
Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults.Arch Intern Med. 2003;163:2716-24.
Zahn C, Sangl J,BiermanAS, et al. Potentially inappropriate medication use in the community-dwelling elderly.JAMA. 2001;286:2823-29.
Klasco RK (Ed): DRUGDEX® System (electronic version). Thomson Micromedex,Greenwood Village,Colorado,USA. Available at: http://www.thomsonhc.com (cited:April 14, 2005).
LaytonAM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris-10 years later: a safe and successful treatment. Br J Dermatol. 1993;129:282-96.
Goulden V,LaytonAM, Cunliffe WJ. Current indications forisotretinoin as a treatment for acne vulgaris. Dermatology. 1995;190:284-7.
McLane J. Supplement: Isotretinoin – A State-of-the-Art Conference. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45:S188-94.
Thiboutot D. Acne: 1991-2001. J Am Acad Dermatol. 2002;47:109-17.
Accutane Product Information. Roche Pharmaceuticals,Nutley,NJ. June 2002.
Property of Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
*C = Covered, copay amount depends on benefits plan
NC = Not Covered Part D drug
PR-B/D = Precertification review criteria to determine coverage as Part B or Part D
PR = Precertification
QL = Quantity Limits
AL = Age Limits
ST = Step-Therapy
‡M EX = Medical Exception
§TOC = Transition of Coverage
*The lists above are subject to change. Not all programs - for example step-therapy, precertification, and quantity limits - are available in all service areas.